Gene sequencing giant Illumina will lay off 51 employees at its San Diego headquarters, the company disclosed in a state filing this week, the latest cost-cutting move by one of the region’s foundational biotech employers.

The layoffs affect workers at the company’s University Towne Centre-area campus at 5200 Illumina Way and will roll out over several months, effective between November 9 and January 8, according to the WARN notice the San Diego Union-Tribune reported on Monday. GenomeWeb, which obtained the same filing, confirmed the headcount on Tuesday.

The cuts span a wide range of roles, from managerial positions to lab technicians, engineers and scientists, an unusually broad cross-section for a layoff of this size. That mix suggests the company is restructuring how its research and operations teams are organized rather than trimming a single program, and comes with severance and outplacement support for affected employees, according to the filing’s terms described in press accounts.

For Illumina, the reductions extend a multi-year stretch of contraction. The company has announced repeated San Diego-area layoffs since 2022 as it fought a costly antitrust battle over its GRAIL cancer-screening subsidiary, which it ultimately divested, and as competition from upstart sequencing rivals compressed the prices it can charge for its core instruments and consumables. Earlier this decade the company employed thousands more in San Diego than it does today, and each new round of cuts reshapes a campus that once symbolized the region’s biotech ambitions.

The broader context is a San Diego biotech cluster under real pressure. Industry analysts and trade press have described a funding environment where venture capital and public-market appetite for genomics and life-science tools firms has thinned, leaving established players like Illumina managing expenses defensively while startups stall or consolidate. The region’s life-sciences office market has softened in parallel, with sublease space rising as companies shrink their footprints, a dynamic that has kept vacancy elevated even as San Diego’s overall economy outperforms Southern California.

Company leadership has framed the current cuts as part of a push to operate more efficiently and redirect spending toward products with clearer paths to growth, including next-generation sequencing platforms and workflow software. Whether that strategy restores growth or merely slows the decline is the question investors and San Diego’s biotech workforce are watching. The company remains one of the largest life-sciences employers in the county and the anchor tenant of a campus corridor that includes hundreds of smaller genomics and diagnostics firms.

For San Diego’s economy, the layoffs are a reminder that the region’s strength in biotech does not insulate it from the sector’s cycles. The 51 positions are small in the context of the county’s overall labor market, but each cut lands in a specialized workforce where displaced scientists and engineers typically re-employ locally, spreading the pain across the cluster. Economic development officials have pressed to diversify the region’s life-sciences base into manufacturing and clinical applications precisely to soften downturns like this one.

Illumina’s WARN filing runs through early January, meaning the final tranche of cuts lands as the company reports year-end results. Local workforce agencies said they have outreach programs ready for affected employees, and the company stated that it remains committed to its San Diego headquarters even as it reshapes the operation’s size and scope.